One-year kidney allograft outcomes do not differ by hepatitis C status of donor

December 14, 2020

Study published in the American Journal of Kidney Diseases (AJKD) shows that kidney allograft outcomes one year post-transplantation in hepatitis C virus (HCV)-negative recipients do not differ by the HCV status of the donor.

Transplant centers are increasingly willing to transplant kidneys from hepatitis C (HCV)-infected donors to HCV-negative recipients. Data on the long-term outcomes following these recipients are sparse. The aim of this single-center, retrospective study was to compare 1-year kidney outcomes in HCV-negative transplant recipients who received an organ either from a donor with or without HCV infection. The 1-year post-transplant kidney outcomes (including allograft function, development of de novo donor specific antibodies, findings on for-cause and surveillance protocol graft biopsies) were similar in these two groups of recipients.
-end-
ARTICLE TITLE: Transplantation of Kidneys From Hepatitis C Virus-Infected Donors to Hepatitis C Virus-Negative Recipients: One-Year Kidney Allograft Outcomes

AUTHORS: Miklos Z. Molnar, MD, PhD, Ambreen Azhar, MD, Makoto Tsujita, MD, PhD, Manish Talwar, MD, Vasanthi Balaraman, MD, Anshul Bhalla, MD, Pradeep S.B. Podila, PhD, MS, Jiten Kothadia, MD, Uchenna A. Agbim, MD, MPH, Benedict Maliakkal, MD, Sanjaya K. Satapathy, MD, MS, Csaba P Kovesdy, MD, Satheesh Nair, MD, and James D. Eason, MD

DOI: 10.1053/j.ajkd.2020.10.017

Full text of article available by email from media contact.

National Kidney Foundation

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.